Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

The prognostic value of minimal residual disease (MRD) in Philadelphia-chromosome-positive (Ph+) childhood acute lymphoblastic leukemia (ALL) treated with tyrosine kinase inhibitors is not fully established. We detected MRD by real-time quantitative polymerase chain reaction (RQ-PCR) of rearranged i...

Descripción completa

Detalles Bibliográficos
Autores principales: Cazzaniga, Giovanni, De Lorenzo, Paola, Alten, Julia, Röttgers, Silja, Hancock, Jeremy, Saha, Vaskar, Castor, Anders, Madsen, Hans O., Gandemer, Virginie, Cavé, Hélène, Leoni, Veronica, Köhler, Rolf, Ferrari, Giulia M., Bleckmann, Kirsten, Pieters, Rob, van der Velden, Vincent, Stary, Jan, Zuna, Jan, Escherich, Gabriele, zur Stadt, Udo, Aricò, Maurizio, Conter, Valentino, Schrappe, Martin, Valsecchi, Maria Grazia, Biondi, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777198/
https://www.ncbi.nlm.nih.gov/pubmed/29079599
http://dx.doi.org/10.3324/haematol.2017.176917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777198/
https://www.ncbi.nlm.nih.gov/pubmed/29079599
http://dx.doi.org/10.3324/haematol.2017.176917

Ejemplares similares